Yüksel Ürün, How Should We Treat

Yüksel Ürün: How Should We Treat mCRPC and HRR Deficiency?

Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared a post on X:

“How should we treat? Patients with metastatic castration-resistant prostate cancer (mCRPC) and HRR deficiency who have already received an ARPI for metastatic castration-sensitive prostate cancer (mCSPC).

  • PARPi monotherapy
  • PARPi plus ARPI
  • Other.”

More posts featuring Yüksel Ürün on Oncodaily.

Ankara University School of Medicine cancer HRR Deficiency mCRPC metastatic castration-resistant prostate cancer OncoDaily Oncology prostate cancer Yüksel Ürün